Table I.
Association of clinicopathological characteristics with immunohistochemical levels of GR in the peritumoral stroma.
| GT expression in the stroma | |||||
|---|---|---|---|---|---|
| Characteristic | No. cases (%) | Strong | Weak | Negative | P-value |
| Age, years | 0.56 | ||||
| ≤50 | 24 (43) | 18 | 5 | 1 | |
| >50 | 32 (57) | 23 | 5 | 4 | |
| Tumor size, mm | 1 | ||||
| <20 | 28 (50) | 21 | 5 | 2 | |
| ≥20 | 28 (50) | 20 | 5 | 3 | |
| Stage | 0.81 | ||||
| T1 | 28 (50) | 21 | 5 | 2 | |
| T2 | 21 (37.5) | 15 | 3 | 3 | |
| T3 | 7 (12.5) | 5 | 2 | 0 | |
| Tumor grade | 0.03 | ||||
| Grade 1 | 10 (17.9) | 10 | 0 | 0 | |
| Grade 2 | 22 (39.2) | 12 | 8 | 2 | |
| Grade 3 | 24 (42.9) | 19 | 2 | 3 | |
| Lymph node status | 0.19 | ||||
| Negative | 29 (51.8) | 24 | 4 | 1 | |
| Positive | 27 (48.2) | 17 | 6 | 4 | |
| ER status | 0.64 | ||||
| Negative | 18 (32.1) | 14 | 2 | 2 | |
| Positive | 38 (67.9) | 27 | 8 | 3 | |
| PR status | 0.39 | ||||
| Negative | 23 (41.1) | 15 | 6 | 2 | |
| Positive | 33 (58.9) | 26 | 4 | 3 | |
| Ki-67 index, % | 0.003 | ||||
| ≤14 | 19 (33.9) | 19 | 0 | 0 | |
| >14 | 37 (66.1) | 22 | 10 | 5 | |
| HER 2 status | 0.2 | ||||
| Negative | 40 (71.4) | 31 | 7 | 2 | |
| Positive | 16 (28.6) | 10 | 3 | 3 | |
| Intrinsic subtype | 0.189 | ||||
| Luminal A | 19 (33.9) | 19 | 0 | 0 | |
| Luminal B/HER2− | 12 (21.4) | 5 | 5 | 2 | |
| Luminal B/HER2+ | 7 (12.5) | 4 | 2 | 1 | |
| HER2+ | 9 (16.1) | 6 | 1 | 2 | |
| Triple negative | 9 (16.1) | 7 | 2 | 0 | |
| GR status in glands | 0.01 | ||||
| Negative | 26 (46.4) | 15 | 6 | 5 | |
| Positive | 30 (53.6) | 26 | 4 | 0 | |
P-values in bold are statistically significant (P<0.05). ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor; GR, glucocorticoid receptor.